Center for Rare Neurological Diseases

Center for Rare Neurological Diseases

The Mass General Center for Rare Neurological Diseases (CRND) aims to eradicate rare disorders of the nervous system by leveraging the power of biological insights towards design and implementation of clinical trials.


Dr. Eichler at meeting
CRND Director Florian Eichler, MD speaks during a team meeting.

The Orphan Drug Act of 1983 defines a rare disease as a disorder or condition that affects fewer than 200,000 persons in the United States. The Center for Rare Neurological Diseases (CRND) focuses on rare diseases of the monogenic type, in which a single gene defect causes disruptive neurological symptoms. The stringent molecular definition of these diseases provides the researcher with an opportunity to leverage unique biology toward scientific discovery.

The CRND seeks to advance treatment of rare diseases and empower the rare disease community. We achieve this through:

  • Advancement of research through biological insight
  • Mentorship of young investigators willing to engage with rare diseases
  • Devotion to translational research, from bench to bedside
  • Exploration of partnerships and collaborations with academia, patients, and industry

CRND info chart

Expand +

Our Mission

The Center for Rare Neurological Diseases (CRND) creates new opportunities to improve the lives of those affected by rare, monogenic neurological disorders by leveraging the unique strengths of these centers, building new alliances based on insights from genomics and biology, patient knowledge and unmet needs, and the advantages of technology, innovation, and expertise.

Our Vision

The CRND envisions a paradigm shift in research and treatment of rare diseases. We endeavor to empower patient populations previously isolated by their rare diseases. Through mentorship, collaboration, and targeted research, the CRND facilitates early proof of concept studies and clinical trials. Together, we are striving to improve the lives of those affected by understudied and newly discovered neurological disorders.


Meet the Team

  • Florian Eichler, MD

    Director, Center for Rare Neurological Diseases
    Associate Professor of Neurology, Harvard Medical School

  • Sue Slaugenhaupt, MD, PhD

    Co-Director, Center for Rare Neurological Diseases

  • Alexander Sherman

    Strategic Network Consultant, Center for Rare Neurological Diseases
    Director of Systems, NCRI

  • Kailey Walsh

    Project Manager, Center for Rare Neurological Diseases

  • Elizabeth Haxton

    Clinical Research Coordinator, Center for Rare Neurological Diseases

  • Rachel Duong

    Clinical Research Coordinator, Center for Rare Neurological Diseases

  • Peter James

    Clinical Research Coordinator, Center for Rare Neurological Diseases

Research Projects

The goal of the CRND is to discover new treatments of rare diseases through translational research. Unlike traditional approaches in academic research, we focus on early identification of knowledge gaps, allowing for a streamlined drug development and trial implementation.

Our current projects:

  • In Preclinical Development: Neurometabolic Diseases of the Newborn, Neurocutaneous Disorders, and Hereditary Neuropathies
  • In Clinical Development: Lysosomal Disorders and Leukodystrophies
  • Ready for Clinical Trials: Leukodystrophies, Poliodystrophies, and Hereditary Neuropathies
CRND project chart
The CRND research strategy, focusing on identification of existing knowledge gaps.

Motivated patient communities and the Neurological Clinical Research Institute contribute to accelerated recruitment and trial implementation through the CRND. The Translational Research Center provides additional services to help facilitate Phase I and II clinical trials. For more information about our current clinical trials and enrollment, please visit the NIH Clinical Trials Registry or the Partners Clinical Trials Site.


Current Mentees

Massachusetts General Hospital and the Partners Residency Program are fortunate to be home to one of the oldest and strongest Neurology Training Programs in the country. This provides an opportunity to introduce promising young investigators and clinicians to rare diseases early in their careers.

  • Patricia Musolino, MD, PhD

    Dr. Musolino is an Instructor in Neurology at Harvard Medical School and MGH. She investigates how genetically determined endothelial cell-to-cell interactions underlie a broad category of vascular and inflammatory diseases of the brain and could be treated by molecular interventions.

  • Reza Seyedsadjadi, MD

    Dr. Seyedsadjadi is a recent and exciting addition to the Neuromuscular Division of Neurology at MGH. He aims to develop imaging biomarker and outcome measures for neuromuscular diseases, deepening our understanding of pathophysiological correlation and aiding in diagnosis, prognostication, and clinical trial implementation.

  • Christopher Stephen, MD

    Dr. Stephen is a neurologist with a special interest in movement disorders, particularly neurogenetic movement disorders such as ataxia, dystonia and Huntington’s disease as well as rare metabolic movement disorders. He is currently faculty at the Massachusetts General Hospital in the movement disorders division, MGH Ataxia Unit and MGH Dystonia Clinic as well as the BWH Performing Arts Clinic .

  • Albert Misko, MD

    Dr. Misko is drawn to pediatric neurology, identifying it as one of the great frontiers of medicine and a field in which translational research can flourish. Excited by the combination of research development and clinical care, Dr. Misko is deeply passionate about scientific discovery and treatment of pediatric neurological disorders.

  • Janice Wong, MD

    Dr. Wong is a clinical fellow in neuromuscular medicine at Brigham and Women’s and Massachusetts General Hospitals from 2016-2017 with an interest in understanding the role of immunological dysfunction in neurodegenerative neuromuscular disorders – including adrenomyeloneuropathy – and its implications for clinical trials.


Industry Partnerships

Private industry holds crucial knowledge on drug development and regulatory processes. The close proximity of MGH to many innovative companies with a shared interest in scientific discovery provides an ideal opportunity for partnership. By de-risking early phase development for rare disease therapies, the CRND makes these conditions attractive for industry engagement and investment. Teaming with Partners HealthCare Innovation helps the CRND work in concert with private industry.

Patient Advocacy Partnerships

Patient engagement is essential for drug development in orphan diseases. We seek to overcome the hierarchies of conventional patient-doctor relationships, encouraging mutual listening and sharing of knowledge and insight within the clinic.

We currently partner with many patient advocacy groups, including the National Tay Sachs and Allied Disease Foundation, the Cystinosis Research Foundation, the Mucolipidosis Type IV Foundation, and Stop ALD/ALDConnect.

For information on how to collaborate with the CRND, contact us.


This 2-year fellowship program focuses on discovering, launching, and building important companies that develop breakthrough products for patients with neurologic and psychiatric disorders. These ventures will reinforce a new paradigm of industry-academic partnership to pioneer novel treatments in neurological diseases. For more information on the fellowship and how to apply, click here.


Gene Therapy

Gene Therapy Program

Gene therapy is an important element of the clinical research being conducted at the CRND and in other groups at MGH. The Gene Therapy Program at MGH serves as a competent resource for investigators developing nucleic acid- or cell-based approaches to disease therapies.

Xandra O. Breakefield, PhD
Xandra O. Breakefield, PhD
Casey A. Macguire, PhD
Casey A. Macguire, PhD
Elizabeth Anne Thiele MD, PhD
Elizabeth Anne Thiele MD, PhD
Scott R. Plotkin, MD
Scott R. Plotkin, MD

Our Projects

gene therapy projects

Think Tank

CRND Think Tank

Collaboration and communication are crucial elements of scientific progress, especially in the rare disease field. In an effort to bring together rare disease experts from across departments, hospitals, and private industry, the CRND participates in quarterly “Think Tank” meetings sponsored by the MGH Division of Clinical Research. These strategic discussions give clinical researchers the opportunity to share developments and collaborate with companies invested in the rare disease space.

  • Florian Eichler, MD

    • Chair
    • Associate Professor of Neurology

  • Maurizio Fava, MD

    • Director, Division of Clinical Research

  • Stephanie Seminara, MD

    • Associate Professor of Medicine, Reproductive Endocrinology

  • Alan Beggs, PhD

    • Director, Manton Center for Orphan Disease Research

  • Jim Gusella, PhD

    • Director, Center for Human Genetic Research

  • Daniel MacArthur, MD

    • Analytic and Translational Genetics Unit

  • Luk H. Vandenbergh, PhD

    • Schepens Eye Research Institute, Mass Eye and Ear

  • Maria Lopez-Bresnahan, MD, MBA

    • VP, Neurology Clinical Development, Vertex Pharmaceuticals

  • Chris Adams PhD, MBA

    Chief Executive Officer, Cydan Development Inc.

  • Phil Reilly, MD, JD

    • Third Rock Ventures

  • Benjamin Raby, MD, MPH

    • Director, Pulmonary Genetics Center

  • Alan Walts, PhD

    • Advent Life Sciences
    • Business Advisor to Henri Termeer

  • Sagar Uday Nigwekar, MD

    • Instructor in Medicine, Department of Medicine

  • Kathryn J. Swoboda, MD, FACM

    • Director, Neurogenetics Program

  • David Alan Sweetser, MD

    • Chief of Medical Genetics
    • Attending Physician in Pediatric Hematology/Oncology

  • Mark J. Pykett, VMD, PhD

    • President & CEO, Agilis Biotherapeutics

  • Jonathan Behr, PhD

    • Market Sector Leader/Exec in Residence, Partners HealthCare Innovation

  • Christopher Coburn

    • VP, Partners HealthCare Innovation

  • Randall Marshall, MD

    • Executive Medical Director, Neuroscience, Retrophin

  • Alice Tsang Shaw, MD, PhD

    • Associate Professor,Department of Medicine
    • Thoracic Oncologist, Thoracic Cancer Program

  • John Staropoli, MD, PhD

    • Associate Medical Director, Rare Disease Innovation Unit, Biogen Idec

  • Timothy Turner, PhD

    • Director of Translational Medicine/MS/Neurology, Genzyme Corporation

  • Ottavio Vitolo, MD, MMSc

    • Sr. Dir., Head of Neuromuscular Clinical Research/ Rare Disease Unit, Pfizer Inc

  • Yu Liu, MD, PhD. MBA

    • Sr. Director, Rare Disease Early Development, Biogen

  • Santiago Arroyo, MD, PhD

    • Chief Medical Officer, Boston Pharmaceuticals

  • Gene Liau, PhD

    • Sr. VP, Head of Gene Therapy, Precision Biosciences

  • Mason Freeman, MD

    • Director, Center for Computational & Integrative Biology (CCIB)/Translational Medicine Group

  • Shinichiro Fuse, PhD

    • MPM Capital

  • Susan Ward, PhD

    • The TAP Collaboration

  • Yulia Grishchuk, MD

    • Research Fellow, MGH Center for Human Genetic Research

  • Sue Slaugenhaupt, PhD

    • Scientific Director, MGH Research Institute

  • Shuli Kulak, MD, MBS

    • Rare Pediatric Diseases – Fortress Biotech, Inc

  • Jeremy Levin, DPhil, MB BChir

    • CEO, Ovid Theraputics

  • Gabriela Apiou, PhD

    • Director, Translational Research Core/MGH

  • Tatiana Koretskaia, MBA

    • Director of Administration and Finance of the MGH Clinical Research Program

  • Irina Antonijevic, MD, PhD

  • Constantine Chinoporos

  • Mark Goldberg, MD

  • Donald Johns, MD

  • Alison Hoffnagle

  • Zongxi Li, PhD


2018 Clinical Research Forum Top Ten | Gene Therapy Halts Progression of Cerebral ALD

2018 Top Ten Herbert Pardes Award Winner: Florian Eichler, MD

Events & Advocacy

Upcoming Events

Stay tuned for upcoming events.

Past Events

American Academy of Neurology (AAN) Annual Meeting
April, 2017

1st Annual Industry-Academia Convocation on Rare Disease
Tuesday, March 21st
5pm - 7pm
Where: 3rd Floor 675 West Kendall
Please RSVP by March 15th to attend the event.

Dr. Eichler and team at Rare Disease day

Charcot-Marie-Tooth Association Boston Branch Meeting
Dr. Reza Seyedsadjadi speaks and answers questions about the MGH Center of Excellence and his ambitions in developing a comprehensive clinic devoted to CMT patients through the MGH neuromuscular center.
March 7, 2017

Rare Disease Day Massachusetts State House
February 28, 2017
Great Hall
24 Beacon Street
Boston MA US 02133

Think Tank on Rare Diseases
“Think Tanks” are meetings with representatives from academia, pharma/biotech etc. to discuss programmatic collaboration. Science and industry experts join together to discuss developments in rare diseases.
November 18, 2016

MGH Clinical Research Day
A chance for MGH investigators to share their work with fellow members of the MGH community.
Thursday, October 6, 2016
O’Keeffe Auditorium and Bulfinch Tents

Think Tank on Rare Diseases
“Think Tanks” are meetings with representatives from academia, pharma/biotech etc. to discuss programmatic collaboration. Science and industry experts join together to discuss developments in rare diseases.
September 23, 2016

2016 ALDConnect Annual Meeting is held in San Diego, CA, providing exciting updates in ALD research and patient advocacy.

Florian Eichler, MD is honored as a 2015 RARE Champion of Hope alongside Ben Lenail and Kathleen O’Sullivan-Fortin of ALDConnect for their outstanding collaboration in research and advocacy on behalf of the rare disease community.
Federal advisory committee for diseases in newborns voted to recommend the addition of ALD to the national newborn screening list.
August 27, 2015

2015 ALDConnect Annual Meeting is held in Boston, bringing together members of the research and patient community to share updates about the organization and recent developments in ALD research.


Contact Us

Kailey Walsh
Project Manager
Phone: 617-643-3799

Other Relevant Resources

Back to Top